Gilead boasts of positive remdesivir data on mortality — but their analysis provokes the skeptics
Gilead is surging again off data that suggest its antiviral remdesivir might improve survival.
The new data come from an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
